Clinical Trials for Prostate Cancer

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with progressing PSMA-positive metastatic castration-resistant prostate cancer after an androgen receptor pathway inhibitor, but without prior chemotherapy for mCRPC or PSMA-targeted therapy, are randomized to standard care alone or with two doses of investigational 177Lu-TLX591. This PSMA-binding antibody delivers lutetium-177 radiation to PSMA-expressing tumors; standard care is enzalutamide, abiraterone, or docetaxel.

ClinicalTrials.gov ID: NCT06520345

PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma that has progressed on or after 177Lu-PSMA-617 receive oral zanzalintinib (XL092) once daily. Zanzalintinib is an investigational multikinase inhibitor targeting VEGFR2, MET, and the TAM-family kinases TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT06568562

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-resistant prostate cancer that has progressed during or after abiraterone receive enzalutamide plus investigational oral SX-682, a CXCR1/2 inhibitor intended to reduce trafficking of immunosuppressive myeloid cells into tumors. Prior enzalutamide or other second-generation androgen-receptor antagonist use and current liver metastases are excluded.

ClinicalTrials.gov ID: NCT06228053

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adult men with high-volume metastatic hormone-sensitive prostate adenocarcinoma, ECOG performance status ≤2, and no prior second-generation androgen receptor pathway inhibitor for advanced disease are randomized to luxdegalutamide plus abiraterone or abiraterone or enzalutamide alone. Luxdegalutamide is an investigational PROTAC that recruits cereblon to drive androgen receptor degradation.

ClinicalTrials.gov ID: NCT06991556

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic cutaneous squamous cell carcinoma refractory to anti-PD-1 therapy receive intravenous ivonescimab every 21 days. Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A.

ClinicalTrials.gov ID: NCT06567314

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with metastatic castration-resistant prostate adenocarcinoma involving bone and/or lymph nodes, without clear visceral metastases, are eligible after progression on an androgen-receptor pathway inhibitor and generally after appropriate life-prolonging therapies. They receive best supportive care plus either pasritamig, an investigational KLK2×CD3 bispecific antibody that redirects T cells against prostate cancer, or placebo.

ClinicalTrials.gov ID: NCT07164443

A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with asymptomatic metastatic castration-resistant prostate cancer that has progressed after a second-generation androgen receptor–axis inhibitor receive investigational ZEN-3694, a BET protein inhibitor, plus bipolar androgen therapy. After radiographic progression, they switch to ZEN-3694 plus enzalutamide.

ClinicalTrials.gov ID: NCT06922318

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-sensitive prostate adenocarcinoma and ECOG performance status 0–1 who have not received an androgen receptor pathway inhibitor or chemotherapy for metastatic disease are randomized to enzalutamide plus mevrometostat or enzalutamide plus placebo. Mevrometostat is an investigational EZH2 inhibitor that reduces histone H3K27 methylation.

ClinicalTrials.gov ID: NCT07028853

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with chemotherapy-naïve mCRPC progressing after exactly one prior androgen receptor pathway inhibitor are randomized to xaluritamig plus abiraterone or investigator’s choice of abiraterone, docetaxel, or cabazitaxel. Xaluritamig is an investigational STEAP1×CD3 bispecific T-cell engager designed to direct T cells against prostate cancer cells.

ClinicalTrials.gov ID: NCT07213674

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with mCRPC progressing after a next-generation hormonal agent and one or two taxane regimens are randomized to opevesostat or an alternative androgen receptor–pathway therapy (abiraterone acetate or enzalutamide). Opevesostat inhibits CYP11A1 to suppress steroid and androgen synthesis and is given with corticosteroid replacement; overall survival is assessed separately by AR ligand-binding-domain mutation status.

ClinicalTrials.gov ID: NCT06136624